Frost & Sullivan Independent Equity Research
DNA Biomedical Solutions Ltd.: Entera’s unsuccessful NASDAQ IPO is not expected to have a significant impact on its clinical plans; Price target affected by a change in the exchange rate.
![dnaLogo dnaLogo](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/dnaLogo-nx7oepmjwr0nqu046yc3t5fs9jyo1sg30b9j97epgk.png)
Company: DNA Biomedical Solutions Ltd.
Sector: Healthcare
Report type: Quarterly update
Published on: February 5, 2018